To assess co-morbidity, quality of life (QOL), work productivity loss, and medical resource utilization (MRU) in patients suffering from glaucoma in Brazil.
The Brazilian NHWS data support that there is an increased burden for patients with glaucoma versus those without the disease. The results indicate glaucoma patients suffer from impairments in quality of life, work/productivity loss and have more co-morbidities and use of medical services than participants without glaucoma. Findings indicate that glaucoma can have a negative impact on patients and the healthcare system.
CONCLUSION
•
LIMITATIONS
Data are self-reported and cannot be verified by patients' medical charts or other objective data.
Glaucoma may be underdiagnosed due to decreased access to physicians in certain regions.
Data are cross-sectional and therefore, do not allow for conclusive causal interpretations. Glaucoma is defined as a manifested progressive optic neuropathy that, if left untreated, leads to irreversible blindness. The most important risk factor is increased intraocular pressure (IOP).
1
Despite the progress in development of effective treatments for eye disease in the last decades, an increasing number of people have functional low vision.
2
After cataract, glaucoma is the second leading cause of blindness. There is a lack of information on the prevalence of glaucoma in Brazil. Most studies report 2%-3% of the adult population of ages 40 years or above [5] [6] [7] is affected.
Most glaucoma related costs (45%) were associated with direct medical costs, but direct nonmedical costs (20%) and indirect costs (35%) were also substantial. Recent economic studies have shown a dramatic increase in the number of patients with glaucoma receiving treatment, but also a reduction in the use of surgical procedures to treat the condition.
Assess functionality, quality of life (QOL), co-morbidities, work and productivity loss, and medical resource utilization (MRU) in patients with glaucoma, and also document the treatment of glaucoma in Brazil.
OBJECTIVE
• The 2011-2012 Brazil National Health and Wellness Survey (NHWS) from Kantar Health was used to collect self-reported data from patients with glaucoma regarding their disease status, severity, and treatment history.
Patients' QOL was measured by the mental component score (MCS) and physical component score (PCS) of the Short Form-12 (SF-12) (mean score of 50 for the general health population).
Loss of productivity was measured using the Work Productivity and Activity Impairment (WPAI) questionnaire, a validated instrument that measures absenteeism (absence from work) and reduced productivity while working and performing daily activities.
Emergency room visits and hospitalization data from the past 6 months were collected to measure MRU.
Co-morbidity information was also assessed for all survey respondents. Comparisons were made between patients with physician-diagnosed glaucoma versus individuals without glaucoma. Statistical analyses were performed to test for statistically significant differences between two comparison groups.
Since glaucoma typically affects adult populations, a group of respondents ages 35 and above was included in the analysis.
METHODOLOGY
The glaucoma group reported lower mean scores of PCS and MCS, more MRU, higher percentages of work loss and activity impairment, and more co-morbidities compared to non-glaucoma group. All comparisons in QOL, MRU, and work/productivity loss between two groups were statistically significant at p < 0.05.
• Top co-morbidities (>10%) among groups are listed in Table 6 . The glaucoma group reported higher rates of anemia, depression, heartburn, insomnia, nail fungus, pain and sleep difficulties prevalence.
• Regarding treatment patterns, timolol, travoprost and latanaprost were the most commonly used treatments for glaucoma in Brazil (see Table 7 ).
• 
